American Heart Journal

iRhythm Technologies Shares Preliminary Fourth Quarter 2023 Highlights and Business Update at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Conference, Partnership, Cardiology, MDR, Interest, Physician, LTCM, SAN, American Heart Journal, IRTC, ZEUS, Zio, MCT, Artificial intelligence, Growth, Patient, Diagnosis

SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 42nd Annual J.P. Morgan Healthcare Conference.
  • An initial $75 million has been funded with the option to draw an additional $75 million over the next year.
  • The proceeds of the transaction will be used to repay the Company’s outstanding debt and for other general corporate purposes.
  • Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com .

DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC)

Retrieved on: 
Monday, February 27, 2023
DREAM, Marketing, CHF, The Texas Heart Institute, LVEF, FACC, Knowledge, American College, MPC 75, Doctor of Philosophy, Heart failure with preserved ejection fraction, MD, Survival, Stroke, HF, MPC, MSB, Heart, MACE, Inflammation, JACC, Research, MESO, Risk, American Heart Journal, Cell, Plaque, Journal, FDA, NYHA, Myocardial infarction, Patient, LVAD, Heart failure, Regenerative medicine, Blood, Mesoblast, Cardiomyopathy, Splenic infarction, US Foods, GI, Nosebleed, Hospital, Membrane protein, Incidence, MI, Pharmaceutical industry, Medical imaging, Cardiology

NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the DREAM-HF Phase 3 trial results in the premier peer-reviewed journal for cardiovascular medicine, the Journal of the American College of Cardiology (JACC).

Key Points: 
  • NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the DREAM-HF Phase 3 trial results in the premier peer-reviewed journal for cardiovascular medicine, the Journal of the American College of Cardiology (JACC).
  • Locally, in the heart, the MPCs can protect cardiac muscle cells from dying and can improve blood flow and energetics.
  • In large blood vessels throughout the body, the reduced inflammation resulting from the activation of MPCs may decrease plaque instability, which is what leads to heart attacks and strokes.
  • “The results of DREAM-HF suggest those patients with heart failure with preserved ejection fraction (HFpEF) and other cardiomyopathies could potentially benefit from MPC therapy as well.

Cardiac Dimensions Included in the New 2021 ESC Guidelines for Heart Failure Management

Retrieved on: 
Wednesday, September 22, 2021
Heart failure, European Heart Journal, ESC, Policy, SMR, Valvular heart disease, Solution, Sale, Percutaneous, European Society of Cardiology, Patient, FMR, American Heart Association, REDUCE, Hospital, Heart, Death, Internal medicine, Adrenal insufficiency, Cardiovascular disease, Disease, Forecasting, American Heart Journal, Algorithm, Carillon, Survival, Safety, City centre, Diagnosis, Treatment, Medical device, Medical imaging, Pharmaceutical industry

KIRKLAND, Wash., Sept. 22, 2021 /PRNewswire/ --Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the mention of their Carillon Mitral Contour System in the 2021 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.

Key Points: 
  • KIRKLAND, Wash., Sept. 22, 2021 /PRNewswire/ --Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the mention of their Carillon Mitral Contour System in the 2021 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.
  • "I'm very pleased to see the Carillon Mitral Contour System mentioned in the 2021 ESC heart failure guidelines," commented Professor Dr. Horst Sievert,Director of the Cardiovascular Center in Frankfurt and the Director of Internal Medicine, Cardiology and Vascular Medicine of the Sankt-Katharinen-Hospital.
  • The guidelines are considered an important tool for the evaluation of heart failure patients with valvular heart disease in Europe.
  • Cardiac Dimensions is a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions.

Pacemaker Market Revenue to Cross USD 4.5 Bn by 2027: Global Market Insights Inc.

Retrieved on: 
Thursday, September 16, 2021
People, Risk, Degenerative disease, Urbanization, Incidence, Hospital, Heart, Smoking, Diabetes, American Heart Journal, Boston Scientific, Wilford Hall Ambulatory Surgical Center, Patient, MRI, CVD, Disease, Mortality, Inflation, USD, CRT, Medtronic, Time-invariant system, Ageing, Heart failure, Myocardial infarction, Growth, ToC, Obesity, Cardiovascular disease, Abbott Laboratories, Atrial fibrillation, Hypertension, GLOBE, Population, Artificial cardiac pacemaker, LivaNova, Journal, Prevalence, Medical device

The implantable pacemaker market is slated to reach USD 4 billion by 2027.

Key Points: 
  • The implantable pacemaker market is slated to reach USD 4 billion by 2027.
  • The biventricular/CRT pacemakers segment will cross USD 328 million by 2027, owing to the increasing prevalence of congestive heart failure.
  • The bradycardia segment captured 35% of the pacemaker market share in 2020, led by the rising incidence of bradycardia.
  • The pacemaker market for the cardiac care centers segment held 13% of revenue share in 2020 and will witness a 5.4% growth rate till 2027.